Eleftherios Mylonakis1, Cornelius J Clancy2, Luis Ostrosky-Zeichner3, Kevin W Garey4, George J Alangaden5, Jose A Vazquez6, Jeffrey S Groeger7, Marc A Judson8, Yuka-Marie Vinagre9, Stephen O Heard10, Fainareti N Zervou1, Ioannis M Zacharioudakis1, Dimitrios P Kontoyiannis11, Peter G Pappas12. 1. Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence. 2. Veterans Affairs Pittsburgh Healthcare System, Division of Infectious Diseases, University of Pittsburgh, Pennsylvania. 3. Division of Infectious Diseases, University of Texas Medical School at Houston and Memorial Hermann Texas Medical Center. 4. University of Houston College of Pharmacy, Texas. 5. Division of Infectious Diseases, Henry Ford Health System, Detroit, Michigan. 6. Department of Medicine, Medical College of Georgia at Georgia Regents University, Augusta. 7. Urgent Care Service, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Division of Pulmonary and Critical Care Medicine, Albany Medical College, New York. 9. Department of Critical Care Medicine, St Vincent Hospital. 10. Department of Anesthesiology, UMass Memorial Medical Center, Worcester, Massachusetts. 11. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston. 12. Division of Infectious Diseases, University of Alabama at Birmingham.
Abstract
BACKGROUND: Microbiologic cultures, the current gold standard diagnostic method for invasive Candida infections, have low specificity and take up to 2-5 days to grow. We present the results of the first extensive multicenter clinical trial of a new nanodiagnostic approach, T2 magnetic resonance (T2MR), for diagnosis of candidemia. METHODS: Blood specimens were collected from 1801 hospitalized patients who had a blood culture ordered for routine standard of care; 250 of them were manually supplemented with concentrations from <1 to 100 colony-forming units (CFUs)/mL for 5 different Candida species. RESULTS: T2MR demonstrated an overall specificity per assay of 99.4% (95% confidence interval [CI], 99.1%-99.6%) with a mean time to negative result of 4.2 ± 0.9 hours. Subanalysis yielded a specificity of 98.9% (95% CI, 98.3%-99.4%) for Candida albicans/Candida tropicalis, 99.3% (95% CI, 98.7%-99.6%) for Candida parapsilosis, and 99.9% (95% CI, 99.7%-100.0%) for Candida krusei/Candida glabrata. The overall sensitivity was found to be 91.1% (95% CI, 86.9%-94.2%) with a mean time of 4.4 ± 1.0 hours for detection and species identification. The subgroup analysis showed a sensitivity of 92.3% (95% CI, 85.4%-96.6%) for C. albicans/C. tropicalis, 94.2% (95% CI, 84.1%-98.8%) for C. parapsilosis, and 88.1% (95% CI, 80.2%-93.7%) for C. krusei/C. glabrata. The limit of detection was 1 CFU/mL for C. tropicalis and C. krusei, 2 CFU/mL for C. albicans and C. glabrata, and 3 CFU/mL for C. parapsilosis. The negative predictive value was estimated to range from 99.5% to 99.0% in a study population with 5% and 10% prevalence of candidemia, respectively. CONCLUSIONS: T2MR is the first fully automated technology that directly analyzes whole blood specimens to identify species without the need for prior isolation of Candida species, and represents a breakthrough shift into a new era of molecular diagnostics. CLINICAL TRIALS REGISTRATION: NCT01752166.
BACKGROUND: Microbiologic cultures, the current gold standard diagnostic method for invasive Candida infections, have low specificity and take up to 2-5 days to grow. We present the results of the first extensive multicenter clinical trial of a new nanodiagnostic approach, T2 magnetic resonance (T2MR), for diagnosis of candidemia. METHODS: Blood specimens were collected from 1801 hospitalized patients who had a blood culture ordered for routine standard of care; 250 of them were manually supplemented with concentrations from <1 to 100 colony-forming units (CFUs)/mL for 5 different Candida species. RESULTS: T2MR demonstrated an overall specificity per assay of 99.4% (95% confidence interval [CI], 99.1%-99.6%) with a mean time to negative result of 4.2 ± 0.9 hours. Subanalysis yielded a specificity of 98.9% (95% CI, 98.3%-99.4%) for Candida albicans/Candida tropicalis, 99.3% (95% CI, 98.7%-99.6%) for Candida parapsilosis, and 99.9% (95% CI, 99.7%-100.0%) for Candida krusei/Candida glabrata. The overall sensitivity was found to be 91.1% (95% CI, 86.9%-94.2%) with a mean time of 4.4 ± 1.0 hours for detection and species identification. The subgroup analysis showed a sensitivity of 92.3% (95% CI, 85.4%-96.6%) for C. albicans/C. tropicalis, 94.2% (95% CI, 84.1%-98.8%) for C. parapsilosis, and 88.1% (95% CI, 80.2%-93.7%) for C. krusei/C. glabrata. The limit of detection was 1 CFU/mL for C. tropicalis and C. krusei, 2 CFU/mL for C. albicans and C. glabrata, and 3 CFU/mL for C. parapsilosis. The negative predictive value was estimated to range from 99.5% to 99.0% in a study population with 5% and 10% prevalence of candidemia, respectively. CONCLUSIONS: T2MR is the first fully automated technology that directly analyzes whole blood specimens to identify species without the need for prior isolation of Candida species, and represents a breakthrough shift into a new era of molecular diagnostics. CLINICAL TRIALS REGISTRATION: NCT01752166.
Authors: J Michael Miller; Matthew J Binnicker; Sheldon Campbell; Karen C Carroll; Kimberle C Chapin; Peter H Gilligan; Mark D Gonzalez; Robert C Jerris; Sue C Kehl; Robin Patel; Bobbi S Pritt; Sandra S Richter; Barbara Robinson-Dunn; Joseph D Schwartzman; James W Snyder; Sam Telford; Elitza S Theel; Richard B Thomson; Melvin P Weinstein; Joseph D Yao Journal: Clin Infect Dis Date: 2018-08-31 Impact factor: 9.079
Authors: Robin Patel; Ephraim L Tsalik; Elizabeth Petzold; Vance G Fowler; Jeffrey D Klausner; Scott Evans Journal: Clin Infect Dis Date: 2016-12-07 Impact factor: 9.079
Authors: John P Bomkamp; Rand Sulaiman; Jennifer L Hartwell; Armisha Desai; Vera C Winn; Justin Wrin; Michelle L Kussin; Jon J Hiles Journal: J Clin Microbiol Date: 2020-02-24 Impact factor: 5.948
Authors: Jessica L Snyder; Heidi Giese; Cheryl Bandoski-Gralinski; Jessica Townsend; Beck E Jacobson; Robert Shivers; Anna M Schotthoefer; Thomas R Fritsche; Clayton Green; Steven M Callister; John A Branda; Thomas J Lowery Journal: J Clin Microbiol Date: 2017-05-31 Impact factor: 5.948